FDA rejects drugmaker's much-anticipated arthritis pill

Drug company Eli Lilly says their much-awaited pill for rheumatoid arthritis has been rejected by the Food and Drug Administration. It’s the company’s second drug development setback since November.A letter to the company from the FDA said that they needed more information about baricitinib’s safety and the best doses, Lilly said Friday in a statement.The drugmaker disagrees with FDA’s conclusions but will work with the agency on a plan to eventually get baracitinib appro